EMERFETAMAB

Investigational

Approval Year

Substance Class	Protein
Protein Type	FC FUSION PROTEIN
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	HOG226RYH1
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

IMMUNOGLOBULIN, ANTI-(HUMAN SIALIC ACID-BINDING IG-LIKE LECTIN 3) (HUMAN MONOCLONAL 1837MNGSSMABC SINGLE-CHAIN VARIABLE FRAGMENT VH1-(GGGGS)3-VL1) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSI

Preferred Name

English

EMERFETAMAB

Official Name

English

EMERFETAMAB [USAN]

Common Name

English

IMMUNOGLOBULIN SCFV-SCFV-SCFC, ANTI-(HOMO SAPIENS CD33 (SIALIC ACID BINDING IG-LIKE LECTIN 3, SIGLEC3, SIGLEC-3, GP67, P67)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), MONOCLONAL ANTIBODY SINGLE CHAIN (SCFV)2-SCFC, BISPECIFIC; IG SCFV-SCFV-SCFC S

Common Name

English

AMG-673

Code

English

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Designated

FDA ORPHAN DRUG

655818

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CAS

2250261-27-7

PRIMARY

FDA UNII

HOG226RYH1

PRIMARY

USAN

JK-129

PRIMARY

CAS

2641417-67-4

NO STRUCTURE GIVEN

INN

11239

PRIMARY

Showing 1 to 5 of 7 entries

Previous1 2Next

Subunit 0

Show entries

From	To
1_22	1_96
1_160	1_231
1_44	1_243
1_278	1_354
1_418	1_486

Showing 1 to 5 of 12 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					HX0GZ7OLW5

MYELOID CELL SURFACE ANTIGEN CD33

TARGET -> INHIBITOR

Interaction Type:

CYTOXICITY

Qualification:

EC50

Amount:

0.0002 NANOMOLAR (average)
AMG 673-mediated cytotoxicity of KG-1 cells. Human PBMCs (10 donors; depleted of autologous CD33+ and CD14+ cells) cocultured (E:T ratio = 5:1)